4
Changes in Ownership
Prelude Therapeutics Inc Filed Acc 0001562180-25-002779
Chief Chemistry Officer bought 100,000 shares at $0.69 ($69,250)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Combs Andrew Chief Chemistry Officer | 2025-03-25 | Purchase | +100,000 | $0.69 | $69,250 | 480,123 | D |
| Open-market purchases · 100,000 sh · avg $0.69 · $69,250 | |||||||
Loading xslF345X05/primarydocument.xml…